Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 125
Appendix A.1
Biographical Sketches of
Committee Members
Peter H. Raven (committee Co-Chair) is a member of the National Academy
of Sciences. He is president emeritus of the Missouri Botanical Garden, after
serving as president for three decades, and is recognized as one of the world’s
leading botanists and advocates for conservation and biodiversity. He received
the National Medal of Science in December 2000. He has also received numer-
ous other awards, including the Society for Conservation Biology Distinguished
Service Award, International Prize for Biology from the government of Japan,
Environmental Prize of the Institute de la Vie, Volvo Environment Prize, Tyler
Prize for Environmental Achievement, and Sasakawa Environment Prize. He is
Engleman Professor of Botany at Washington University and chairman of the
National Geographic Society’s Committee for Research and Exploration. He has
served as president of the American Association for the Advancement of Sci-
ence and as a member of the President’s Committee of Advisors on Science and
Technology. He served for 12 years as home secretary of the National Academy
of Sciences. He is a member of academies of science in Argentina, China, India,
Italy, and Russia. He was first chair of the U.S. Civilian Research and Develop-
ment Foundation. He has received honorary degrees from universities throughout
the world.
Valentin Vlassov (committee Co-Chair) is a member of the Russian Academy
of Sciences (RAS) and vice chairman of the Siberian Branch of the Russian
Academy of Sciences since 2008. He also currently serves as the director of the
Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch
of RAS and as professor of molecular biology and chair of the Department of
Molecular Biology at Novosibirsk State University. He also is chair of the Bio-
125
OCR for page 126
126 APPENDIX A.1
logical Council of the Siberian Branch of RAS, which coordinates research at
biological academic institutes in Siberia. He has more than 300 scientific publica-
tions that include research on RNA structure, antisense technologies, and circulat-
ing nucleic acids. He has received several awards, including the State Prize for
scientific achievement. Current activity is focused on development of approaches
for translational medicine, including postgenomic technologies-based diagnostic
methods, design of gene-targeted therapeutics, and cell technologies.
Kavita M. Berger is the associate program director of the Center for Science,
Technology, and Security Policy at the American Association for the Advance-
ment of Science (AAAS). Since joining AAAS in 2006, she has addressed
complex biosecurity policy issues, such as personnel reliability and misuse of
biological research, by actively interacting with the scientific community, facili-
tating open dialogue between the scientific and security communities, and provid-
ing a voice for the scientific community in timely policy debates. Through these
projects and other activities, she has helped enable scientists to contribute to
addressing biosecurity risks at the local, national, and international levels. Dur-
ing a short absence from AAAS, she worked with the Presidential Commission
for the Study of Bioethical Issues as the staff lead on evaluation of the ethical
issues associated with pediatric medical countermeasures research. She received
her Ph.D. degree in genetics and molecular biology at Emory University and
conducted her postdoctoral research on preclinical research and development on
HIV and smallpox vaccines.
David Franz (Consultant) has recently served as vice president and chief biologi-
cal scientist of MRIGlobal and senior advisor (biosecurity engagement) to the
Office of the Assistant to the Secretary of Defense for Nuclear, Chemical, and
Biological Defense Programs. Dr. Franz was the chief inspector on three UN
Special Commission biological warfare missions to Iraq and served as technical
advisor on long-term monitoring. He also served as a member of the first two
U.S.-U.K. teams that visited Russia in support of the Trilateral Joint Statement
on Biological Weapons and as a member of the Trilateral Experts’ Committee
for biological weapons negotiations. Dr. Franz served in the U.S. Army Medical
Research and Materiel Command for 23 of 27 years on active duty and retired as
colonel. He served as commander of the U.S. Army Medical Research Institute
of Infectious Diseases (USAMRIID) and as deputy commander of the Medical
Research and Materiel Command. Prior to joining the Command, he served as
group veterinarian for the 10th Special Forces Group (Airborne). The current
focus of his activities relates to the role of international engagement in the life
sciences as a component of national security policy. Dr. Franz holds a D.V.M.
from Kansas State University and a Ph.D. in physiology from Baylor College of
Medicine.
OCR for page 127
APPENDIX A.1 127
Tatiana Gremyakova is chief science coordinator of biotechnology at the Inter-
national Science and Technology Center (ISTC) in Moscow. She graduated from
the Medical-Biological Faculty of Moscow Medical Institute (1979) and received
her Ph.D. degree at the Moscow Mechnikov Institute of Vaccine and Sera (1983).
She joined the State Research Center for Applied Microbiology in Obolensk,
and received her doctor of medical sciences degree in 2004. Her areas of inter-
est are microbiology, biochemistry, diagnostics, drug and vaccine development,
biosafety, and biosecurity. She is the author of nearly 70 Russian and international
scientific publications. She has served as chair of the ISTC’s BioCom, where
she developed and managed projects with governmental and business partners.
She has participated in developing more than 150 international projects (R&D
and science infrastructure) in medicine, pharmacology, agriculture, industrial
biotech, biosafety, and physical security in Russia, Armenia, Belarus, Georgia,
and Kazakhstan. Currently, she serves as an expert at the Analytical Center of the
Russian Government, where she supports projects of interest to the President’s
Commission on Modernization and Technological Development. She is a member
of the International Society of Infectious Diseases.
Oleg Kiselev is a member of the Russian Academy of Medical Sciences. He is
director of the Research Institute of Influenza in St. Petersburg. Currently a pro-
fessor of molecular virology, he graduated from the internal medicine faculty of
the I.P. Pavlov First Medical Institute. In 1972, he received his Ph.D. degree in
biochemical genetics at this Institute in mitochondrial biogenesis, and in 1979,
he received a doctor of science degree in molecular biology. Later, he moved
to the Ministry of Microbiological Industry as head of the Division of Genetic
Engineering for development and manufacture of recombinant interferon. He
received patents for IL-2 and IFN-alpha producer strains and technology for their
production. Beginning in 1988, he has served as director of the Research Institute
of Influenza. The institute has become the national World Health Organization
(WHO) Center for Influenza Control and Surveillance. The institute includes a
Clinical Department headed by Professor Kiselev, where every year new influ-
enza vaccines are tested and approved according to WHO recommendations. He
has been the project leader on a number of international grants: DelNS–vaccine
development and production (Green Hills Biotechnology); Antiinfluenza siRNA
(SirnaOmics); new antiviral drugs and production technology—Triazavirin—with
wide spectra of antiviral activity; and others in the field of influenza. He has pub-
lished 12 books in the fields of influenza, prions, herpes virus infection treatment,
papilloma virus pathogenesis, and cancer development.
James LeDuc is director of the Galveston National Laboratory (GNL) located on
the campus of the University of Texas Medical Branch in Galveston, Texas. He is
also a professor in the Department of Microbiology and Immunology and holds
the Robert E. Shope and John S. Dunn Distinguished Chair in Global Health. He
OCR for page 128
128 APPENDIX A.1
relocated to Galveston in 2006 from the Centers for Disease Control and Preven-
tion (CDC), where he was the influenza coordinator. He also served as director,
Division of Viral and Rickettsial Diseases, coordinating research activities, pre-
vention initiatives, and outbreak investigations for viral and rickettsial pathogens,
including viral hemorrhagic fevers, influenza and other respiratory infections,
childhood viral diseases, and newly emerging diseases such as SARS. He served
as the associate director for global health in the Office of the Director, National
Center for Infectious Diseases at CDC, and he was a medical officer in charge
of arboviruses and viral hemorrhagic fevers at the World Health Organization in
Geneva, Switzerland (1992–1996). He also held leadership positions during a
23-year career as a U.S. Army officer in the medical research and development
command, with assignments in Brazil, in Panama, and at various locations in the
United States, including the Walter Reed Army Institute of Research and the U.S.
Army Medical Research Institute of Infectious Diseases. He has published more
than 200 scientific articles and book chapters.
Sergey Netesov is a corresponding member of the Russian Academy of Sciences.
He has been vice rector (research) at Novosibirsk State University since 2007.
Previously, he served for 30 years at the State Research Center of Virology and
Biotechnology, Vector; and in 1990, he became its deputy director for research.
He graduated from Novosibirsk State University (1975), joined Vector (1977),
and received his Ph.D. (1983) and doctor of biology (1993) degrees. He is a
member of the European Academy of Sciences, American Society for Virology,
American and European Biosafety Associations, and the Russian Society of
Epidemiologists, Microbiologists, and Parasitologists; he is also a member of
the Filovirus Study Group of ICTV. In the beginning of his research career he
developed original methods of isolation of restriction endonucleases and reverse
transcriptase. Later, he was a principal investigator (PI) of a few national projects
of pioneer sequencing the genomes of the following viruses: Marburg, Ebola,
Venezuelan Equine Encephalitis (VEEV), Eastern and Western Equine encepha-
litis, tick-borne encephalitis, and influenza. He also was a PI of the reverse genet-
ics project on the VEE virus reconstruction from cDNA fragments. He also was
involved in the development of an inactivated hepatitis A vaccine and recombi-
nant hepatitis B vaccine and ran a project on the development of a recombinant
vaccine against VEE virus. Recently, he successfully completed a few projects
focused on the study of molecular diversity and epidemiology of viral hepatitis
in Siberia and participated in other molecular epidemiology projects. Dr. Netesov
is twice a winner of the prize awarded by the government of the Russian Federa-
tion in the area of science and technology (1998 and 2006). His research interests
include virology, biotechnology, and biosafety. He is the author of more than 140
publications in Russian and international journals.
OCR for page 129
APPENDIX A.1 129
Peter Palese is a member of the National Academy of Sciences. He is professor
of microbiology and chair of the Department of Microbiology at the Mount Sinai
School of Medicine. His research is in the area of RNA-containing viruses with a
special emphasis on influenza viruses. Specifically, he established the first genetic
maps for influenza A, B, and C viruses, identified the function of several viral
genes, and defined the mechanism of neuraminidase inhibitors (which are now
FDA-approved antivirals). He was also a pioneer in the field of reverse genetics
for negative strand RNA viruses, which allows the introduction of site-specific
mutations into the genomes of these viruses. This technique is crucial for the
study of the structure and function relationships of viral genes, for investigation
of viral pathogenicity, and for development and manufacture of novel vaccines. In
addition, an improvement of the technique has been effectively used by him and
his colleagues to reconstruct and study the pathogenicity of the highly virulent,
but extinct, 1918 pandemic influenza virus. His recent work in collaboration with
Garcia-Sastre has revealed that most negative strand RNA viruses possess pro-
teins with interferon antagonist activity, enabling them to counteract the antiviral
response of the infected host. At present, he serves on the editorial board for the
Proceedings of the National Academy of Sciences. Dr. Palese was president of the
Harvey Society in 2004, president of the American Society for Virology in 2005,
a recipient of the Robert Koch Prize in 2006, and a recipient of the European
Virology Award (EVA) in 2010.
Richard Witter is a member of the National Academy of Sciences. He served as
a veterinary medical officer with the U.S. Department of Agriculture-Agricultural
Research Service (ARS) Avian Disease and Oncology Laboratory (ADOL) in
East Lansing, Michigan, for 38 years (1964–2002). He currently serves as col-
laborator with the ADOL and as adjunct professor with the Department of Patho-
biology and Clinical Investigations at Michigan State University. He helped
develop the first successful vaccine in the United States against Marek’s disease
and has documented the evolution of this virus to greater virulence. He has
received numerous awards and recognition for his research. For more than 22
years, as director and research leader of ADOL, he administered a multidisci-
plinary research program on the biology of important avian viral neoplasms, as
well as programs on recombinant DNA vaccines, immunogenetics, transgenic
chickens, and genome mapping. He returned to the bench in 1998, where he
pursued research on Marek’s disease and avian leukosis until his retirement in
2002. He has been active in international activities involving grants programs
in the Middle East and Central Asia. He helped initiate the ARS-Former Soviet
Union Scientific Cooperation Program and has served as a scientific consultant to
this program since its inception. He received his B.S. and D.V.M. from Michigan
State University and his M.S. and Ph.D. from Cornell University.
OCR for page 130
130 APPENDIX A.1
Russ Zajtchuk, a national expert in telemedicine, is currently president of
Chicago Hospitals International. For more than 27 years, he served in various
positions in the U.S. Army, most recently as commanding general of the Army
Medical Research and Material Command at Fort Detrick, Maryland, where he
led development of a sophisticated telecommunications infrastructure to speed
diagnostics, lab analyses, and consulting expertise worldwide. He is a cardiovas-
cular surgeon who was professor and chairman of the division of cardiothoracic
surgery at the Uniformed Services University of the Health Sciences. He also
served as assistant surgeon general for research and development for the Depart-
ment of the Army and as chief operating officer for the Department of Defense
telemedicine test bed. He has served on several committees of the National
Research Council concerning scientific developments in the former Soviet Union.
Sergey Zavriev is a corresponding member of the Russian Academy of Agricul-
tural Sciences. He is head of the Molecular Diagnostics Department and head
of the International Scientific Relation Department at the Shemyakin-Ovchin-
nikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences.
His research during the past 10 years has been aimed at investigating plant
virus genome structure and expression; cloning and expression of virus-specific
genes, allergens and other proteins, and their application for functional studies;
producing antibodies against different recombinant antigens, including aller-
gens; development of technologies for PCR and RT-PCR-based detection of
DNA- and RNA-containing pathogens; immuno-PCR technologies; and diag-
nostic kit production. He was previously a visiting professor in the Department
of Plant Pathology at the University of North Carolina, where he worked on
plant molecular virology. He has been awarded several international grants from
INCO-Copernicus, INTAS, and European Commission FP6-FP7. He is a member
of several international teams participating in the meetings and symposia on stra-
tegic studies of bioterrorism and biosecurity problems. He is the author of more
than 140 articles, book chapters, and patents.
